跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 65,622 条关于
“UBE3A-AS”
全部
65,622
临床试验
28,341
药物
779
机构
486
资讯
36,016
去年
Ionis Pharmaceuticals' ION582 Receives FDA Fast Track Designation for Angelman Syndrome Treatment
去年
Ultragenyx's GTX-102 Shows Promise in Angelman Syndrome Phase 1/2 Trial
去年
Ultragenyx Doses First Patient in Phase 3 Aspire Study of GTX-102 for Angelman Syndrome
去年
Quiver Bioscience Names Co-Founder Graham Dempsey CEO to Advance Nav1.7-Targeting ASO for Chronic Pain
2个月前
Ionis Completes Enrollment in Pivotal Cohort of Phase 3 REVEAL Study for Obudanersen in Angelman Syndrome
3个月前
Oak Hill Bio to Go Public via SPAC Merger, Secures $175 Million to Advance Rugonersen for Angelman Syndrome Through Phase 3
去年
Ionis' ION582 for Angelman Syndrome Advances to Phase 3 Trial
去年
FDA Clears IND for MavriX Bio's Gene Therapy for Angelman Syndrome, First-in-Human Trial to Begin in 2025
去年
Oak Hill Bio Advances Rugonersen for Angelman Syndrome Following Promising Phase 1 Results Published in Nature Medicine
去年
Ionis Advances Antisense Therapy for Angelman Syndrome to Phase 3 Following Promising Clinical Results
第 1 页,共 3602 页
上一页
下一页